## NDAQ: Nasdaq, Inc. - XLF: Financial Services

### Executive Summary

No thesis match: PEG 1.47 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($89.77)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Annual Changes to the Nasdaq-100 Index®**
- Source: The Globe and Mail | 20251213T015952 | Neutral | Relevance: 84%
- Nasdaq announced the annual reconstitution of the Nasdaq-100 Index®, effective December 22, 2025. Six companies will be added, including Alnylam Pharmaceuticals and Western Digital Corp., while six others, such as Biogen Inc. and Lululemon Athletica Inc., will be removed. The Nasdaq-100 Index tracks 100 of the largest non-financial companies on the Nasdaq Stock Market and underpins over 200 tracking products with more than $600 billion in assets under management.

**2. NYSE Content Advisory: Pre-Market Update + Seven of the Top 10 IPOs in 2025 List on NYSE**
- Source: Financial Times | 20251215T135719 | Somewhat-Bullish | Relevance: 73%
- The NYSE provides a daily pre-market update, noting that stocks are fractionally higher to start a busy economic data week. Seven of the top 10 IPOs in 2025 debuted on the NYSE, and NYSE President Lynn Martin highlighted maintaining momentum and simplifying the path for companies to go public as a 2026 priority. Baron Capital launched new active ETFs, and Dr. Martin Makary discussed modernizing FDA processes for drug development.

**3. B. Riley (RILY.US) Submits 10-Q Filing to Nasdaq in Effort to Maintain Listing After Facing Delisting Risks**
- Source: 富途牛牛 | 20251216T070925 | Neutral | Relevance: 71%
- B. Riley Financial Inc. (RILY.US) has submitted its overdue second-quarter report (10-Q) to the SEC, a critical step towards meeting Nasdaq's listing requirements and avoiding delisting. This filing disclosed a profit for the quarter, significantly improving from a loss in the previous year, and the company is working to submit its third-quarter report before the January 20 deadline. The move comes after the company faced financial reporting deficiencies, investment losses, and an ongoing civil investigation, which led to repeated delisting threats from Nasdaq.

**4. Cim Investment Management Inc. Has $6.35 Million Holdings in Equinix, Inc. $EQIX**
- Source: MarketBeat | 20251214T102527 | Neutral | Relevance: 65%
- Cim Investment Management Inc. significantly increased its stake in Equinix, Inc. (NASDAQ:EQIX) during the second quarter, growing its holdings by 99.7% to a total value of $6.35 million. This makes Equinix the 16th largest holding in their portfolio, representing 1.2% of their total assets. The article also details recent stock performance, earnings, dividend information, insider transactions, and analyst ratings for Equinix.

**5. Datavault AI Announces Hockey Hall of Famer Jeremy Roenick**
- Source: GlobeNewswire | 20251215T075500 | Somewhat-Bullish | Relevance: 64%
- Datavault AI announced that Hockey Hall of Famer Jeremy Roenick is joining the company to lead its Sports and Entertainment initiative, focusing on the International NIL Exchange. Roenick will leverage his expertise to expand the platform, which uses Datavault AI's patented technologies to enable athletes and entertainers to monetize their brands securely through tokenized assets and smart contracts on the Information Data Exchange®. This move aims to revolutionize how sports data is monetized and empower creators with financial power and global reach.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Barclays | $114 | $109 | +5% |
| 2025-11-20 | Morgan Stanley | $110 | $97 | +13% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Barclays | main | Overweight |
| 2025-11-20 | Morgan Stanley | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($2.76M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.0% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.4% (+6.9%)
- Investor AB: 10.2% (0.0%)
- Blackrock Inc.: 7.0% (+8.3%)
- Wellington Managemen: 7.0% (-3.5%)
- Massachusetts Financ: 4.6% (-3.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.47 suggests fair value with growth premium. Forward P/E 24.3x stretched relative to 11% growth. Quality metrics strong (margin 20%). Analyst sentiment positive (2 raises, avg +9%). Insider selling cluster ($2.8M in 90 days), potential headwind. Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $53.3B |
| Beta | 1.02 |
| 52W Range | $64.84 - $97.63 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.47 |
| Forward P/E | 24.3 |
| Current P/E | 27.1 |
| YoY Growth | 11.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 0.5% to 4.0% (+3.4% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 73rd percentile. MRS_5 at 1.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.96% (CS: 74) | Strong |
| RSI_14 | 64.1 | Neutral |
| MACD Histogram | 0.49 | Bullish |
| vs SMA20 | 1.038x | Above |
| vs SMA50 | 1.049x | Above |
| vs SMA200 | 1.083x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $92.93
- **Stop Loss:** $89.77 (3.4% risk)
- **Target:** $96.09 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 379
- **Position Value:** $35,220.47
- **Portfolio %:** 35.22%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | MOMENTUM (Zone F) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-01-28 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.85 | $0.88 | +3.7% |
| 2025Q2 | $0.81 | $0.85 | +4.6% |
| 2025Q1 | $0.77 | $0.79 | +2.5% |
| 2024Q4 | $0.75 | $0.76 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*